tetano
Editor, Senior Moderator
Crit Care Explor
. 2021 Jul 16;3(7):e0498.
doi: 10.1097/CCE.0000000000000498. eCollection 2021 Jul.
Natriuretic Peptide Levels and Clinical Outcomes Among Patients Hospitalized With Coronavirus Disease 2019 Infection
M Imran Aslam[SUP] 1 [/SUP], Anum Minhas[SUP] 1 2 [/SUP], Anahita Ghorbani[SUP] 1 [/SUP], Julie K Shade[SUP] 3 [/SUP], Vivek Jani[SUP] 1 [/SUP], Steven Hsu[SUP] 1 [/SUP], Kavita Sharma[SUP] 1 [/SUP], Daniela Cihakova[SUP] 4 [/SUP], Allison G Hays[SUP] 1 [/SUP], Nisha A Gilotra[SUP] 1 [/SUP]
Affiliations
Abstract
Objectives: There is increasing evidence of cardiovascular morbidity associated with severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019). Pro-B-type natriuretic peptide is a biomarker of myocardial stress, associated with various respiratory and cardiac outcomes. We hypothesized that pro-B-type natriuretic peptide level would be associated with mortality and clinical outcomes in hospitalized coronavirus disease 2019 patients.
Design: We performed a retrospective analysis using adjusted logistic and linear regression to assess the association of admission pro-B-type natriuretic peptide (analyzed by both cutoff > 125 pg/mL and log transformed pro-B-type natriuretic peptide) with clinical outcomes. We additionally treated body mass index, a confounder of both pro-B-type natriuretic peptide levels and coronavirus disease 2019 outcomes, as an ordinal variable.
Setting: We reviewed hospitalized patients with coronavirus disease 2019 who had a pro-B-type natriuretic peptide level measured within 48 hours of admission between March 1, and August 31, 2020, from a multihospital U.S. health system.
Patients: Adult patients (≥ 18 yr old; n = 1232) with confirmed coronavirus disease 2019 admitted to the health system.
Interventions: None.
Measurements and main results: After adjustment for demographics, comorbidities, and troponin I level, higher pro-B-type natriuretic peptide level was significantly associated with death and secondary outcomes of new heart failure, length of stay, ICU duration, and need for ventilation among hospitalized coronavirus disease 2019 patients. This significance persisted after adjustment for body mass index as an ordinal variable. The adjusted hazard ratio of death for log transformed pro-B-type natriuretic peptide was 1.56 (95% CI, 1.23-1.97; p < 0.0001).
Conclusions: Further investigation is warranted on the utility of pro-B-type natriuretic peptide for clinical prognostication in coronavirus disease 2019 as well as implications of abnormal pro-B-type natriuretic peptide in the underlying pathophysiology of coronavirus disease 2019-related myocardial injury.
Keywords: biomarkers; coronavirus disease 2019; heart failure; natriuretic peptide; obesity; pandemic.
. 2021 Jul 16;3(7):e0498.
doi: 10.1097/CCE.0000000000000498. eCollection 2021 Jul.
Natriuretic Peptide Levels and Clinical Outcomes Among Patients Hospitalized With Coronavirus Disease 2019 Infection
M Imran Aslam[SUP] 1 [/SUP], Anum Minhas[SUP] 1 2 [/SUP], Anahita Ghorbani[SUP] 1 [/SUP], Julie K Shade[SUP] 3 [/SUP], Vivek Jani[SUP] 1 [/SUP], Steven Hsu[SUP] 1 [/SUP], Kavita Sharma[SUP] 1 [/SUP], Daniela Cihakova[SUP] 4 [/SUP], Allison G Hays[SUP] 1 [/SUP], Nisha A Gilotra[SUP] 1 [/SUP]
Affiliations
- PMID: 34291225
- PMCID: PMC8288900
- DOI: 10.1097/CCE.0000000000000498
Abstract
Objectives: There is increasing evidence of cardiovascular morbidity associated with severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019). Pro-B-type natriuretic peptide is a biomarker of myocardial stress, associated with various respiratory and cardiac outcomes. We hypothesized that pro-B-type natriuretic peptide level would be associated with mortality and clinical outcomes in hospitalized coronavirus disease 2019 patients.
Design: We performed a retrospective analysis using adjusted logistic and linear regression to assess the association of admission pro-B-type natriuretic peptide (analyzed by both cutoff > 125 pg/mL and log transformed pro-B-type natriuretic peptide) with clinical outcomes. We additionally treated body mass index, a confounder of both pro-B-type natriuretic peptide levels and coronavirus disease 2019 outcomes, as an ordinal variable.
Setting: We reviewed hospitalized patients with coronavirus disease 2019 who had a pro-B-type natriuretic peptide level measured within 48 hours of admission between March 1, and August 31, 2020, from a multihospital U.S. health system.
Patients: Adult patients (≥ 18 yr old; n = 1232) with confirmed coronavirus disease 2019 admitted to the health system.
Interventions: None.
Measurements and main results: After adjustment for demographics, comorbidities, and troponin I level, higher pro-B-type natriuretic peptide level was significantly associated with death and secondary outcomes of new heart failure, length of stay, ICU duration, and need for ventilation among hospitalized coronavirus disease 2019 patients. This significance persisted after adjustment for body mass index as an ordinal variable. The adjusted hazard ratio of death for log transformed pro-B-type natriuretic peptide was 1.56 (95% CI, 1.23-1.97; p < 0.0001).
Conclusions: Further investigation is warranted on the utility of pro-B-type natriuretic peptide for clinical prognostication in coronavirus disease 2019 as well as implications of abnormal pro-B-type natriuretic peptide in the underlying pathophysiology of coronavirus disease 2019-related myocardial injury.
Keywords: biomarkers; coronavirus disease 2019; heart failure; natriuretic peptide; obesity; pandemic.